# Safety, Tolerability, Efficacy and Immunogenicity of an Influenza A Vaccine (FP-01.1) in Healthy Volunteers Following Virus Challenge

> **NCT02071329** · PHASE1,PHASE2 · COMPLETED · sponsor: **Immune Targeting Systems Ltd** · enrollment: 111 (actual)

## Conditions studied

- Influenza A

## Interventions

- **DRUG:** Vaccine FP-01.1
- **DRUG:** Placebo
- **OTHER:** Virus Challenge

## Key facts

- **NCT ID:** NCT02071329
- **Lead sponsor:** Immune Targeting Systems Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 111 (ACTUAL)
- **Last updated:** 2016-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02071329

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02071329, "Safety, Tolerability, Efficacy and Immunogenicity of an Influenza A Vaccine (FP-01.1) in Healthy Volunteers Following Virus Challenge". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02071329. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*